(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 October 2025 (16.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/217164 A1

(51) International Patent Classification:
C07D 401/14 (2006.01) *A61P 37/06* (2006.01)
A61K 31/4523 (2006.01) *C12N 9/12* (2006.01)
A61K 31/519 (2006.01)

(21) International Application Number:
PCT/US2025/023654

(22) International Filing Date:
08 April 2025 (08.04.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/631,500 09 April 2024 (09.04.2024) US

(71) Applicant: **ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI** [US/US]; One Gustave L. Levy Place, New York, New York 10029 (US).

(72) Inventors: **HO, Hsi-En**; c/o Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York 10029 (US). **CUNNINGHAM RUNDLES, Charlotte**; c/o Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York 10029 (US). **RADIGAN, Lin K.**; c/o Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York 10029 (US).

(74) Agent: **SHEEHAN, Teige P.**; HESLIN ROTHENBERG FARLEY & MESITI P.C., 5 Columbia Circle, Albany, New York 12207 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2025/217164 A1

(54) Title: TREATING INFLAMMATORY COMMON VARIABLE IMMUNODEFICIENCY WITH A BRUTON'S TYROSINE KINASE INHIBITOR

(57) Abstract: Provided is a method for treating common variable immunodeficiency (CVID), or for treating an inflammatory-CVID condition resulting from bacterial translocation, including administering to the human patient a therapeutically effective amount of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib). Also provided is a method of inhibiting secretion of an inflammatory factor by peripheral blood mononuclear cells, including contacting the cells with rilzabrutinib.